Slide 1: This is Sobi – Investor Presentation July 2024
This is SobiD Investor Presentation July 2024
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Table of contents
Table of contents Slide Sobi Key facts and business model 4 Latest results - Q4 and Full year 2023 and business area update 12 Sustainability at Sobi 27 Pipeline and upcoming news flow 31 IR contacts 35 Notes 36
Slide 4: Sobi's mission is to transform the lives of people with rare and debilitating diseases
Sobi’s mission is to transform the lives of people with rare and debilitating diseases Sobi Strategy Growing Portfolio Strategic Portfolio 1,800 employees focused on rare diseases Listed on Nasdaq Lead in Haematology Operating in 30 countries and serving ̴70 markets Stockholm: SOBI 5 medicines in la
Slide 5: Rare diseases are an attractive market and expected to grow faster than general pharma
Rare diseases are an attractive market and expected to grow faster than general pharma • ~7,000 rare disease have been identified with only an Sobi well positioned within rare diseases estimated 130 with marketed treatments • High medical unmet need and treatments offering significant Current Sobi A
Slide 6: Business model - source, develop and commercialise in the rare disease space
Business model - source, develop and commercialise in the rare disease space 2018 2019 2020 2022 2023 Acquisitions Source Licensing 7 medicines in 9 projects in development Develop (phase 2 through registration) Europe +6% Commercialise 2023: Revenue: SEK 22,123 M North America + 6% (+12% at CER) In
Slide 7: Strong record of successful achievements in delivering medicines to rare disease patients
Strong record of successful achievements in delivering medicines to rare disease patients around the world Selected examples from the Sobi portfolio Source Novimmune Dova Apellis CTI Pharma ITP - FDA approval 2018 PNH - EU approval 2021 MF – FDA approval 2022 pHLH - FDA approval 2018 EU approval 202
Slide 8: Growth driven by core business area and all regions
Growth driven by core business area and all regions Sales (SEK B) Sales (SEK B) Specialty Care Immunology Haematology Europe North America Royalty Rest of World 22.1 22.1 18.8 18.8 15.3 15.5 15.3 15.5 14.2 14.2 9.1 9.1 6.5 6.5 2017 2018 2019 2020 2021 2022 2023 2017 2018 2019 2020 2021 2022 2023 8
Slide 9: Strategic portfolio set to be the main contributor to our revenue
Strategic portfolio set to be the main contributor to our revenue Strong fundamentals for future growth • Strategic Portfolio with ongoing launches and international diversification Strategic portfolio including Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo, Zynlonta, Potential new medicines* Beyfort
Slide 10: Strategic portfolio and execution of our strategy set to deliver strong growth outlook
Strategic portfolio and execution of our strategy set to deliver strong growth outlook C3G / Sobi Strategy IC-MPGN sHLH / Lead in Haematology MAS SEL-212 Capture the value of the pipeline Efanesoctocog New Indications* alfa Grow Immunology New medicines* and Specialty Care Geographical expansion Go
Slide 11: Management Team
Management Team 11 sobi.com/executive committee
Slide 12: Latest results - Q2 2024 and business area update
Latest results - Q2 2024 and business area update
Slide 13: Strategic portfolio delivering top-line growth
Strategic portfolio delivering top-line growth Continued pipeline momentum Sobi strategy High double-digit performance at CER Revenue Q2 - SEK 5,442 M, +11% (excluding sales of Doptelet in China Q2 2023 growth was 26%) Lead in Haematology Adjusted EBITA margin 28% Strategic portfolio1 accounting for
Slide 14: Strong momentum delivering 11% growth in Q2
Strong momentum delivering 11% growth in Q2 Driven by launch medicines and regional growth Revenue by segment Revenue by region Q2 2024 change ratio Q2 2024 change ratio SEK M % % SEK M % % Haematology 3,866 +13 71 Europe 2,265 +13 42 North America 2,021 +38 37 – Haemophilia 2,315 +11 60 Internation
Slide 15: Strategic portfolio 41% of revenue in Q2
Strategic portfolio 41% of revenue in Q2 Q2 Q2 SEK M Change at CER H1 2024 2024 2023 Aspaveli/Empaveli 251 144 77% 490 Doptelet (excluding China) 928 567 61% 1,684 Gamifant 522 491 4% 960 Vonjo 347 36 >200% 667 Zynlonta 25 6 >200% 38 Altuviiio royalty 139 14 >200% 248 Beyfortus royalty 7 - n/a 325 S
Slide 16: Strategic portfolio strongly contributing to revenue
Strategic portfolio strongly contributing to revenue Delivering treatments to patients with greatest unmet need Portfolio segments and Revenue, MSEK • EU approval of Altuvoct contribution to growth % change CER strengthening the strategic portfolio from Q3 2024 5,442 • Royalties of Beyfortus and 4,8
Slide 17: Execution of our strategy and pipeline delivery set to drive a strong growth outlook
Execution of our strategy and pipeline delivery set to drive a strong growth outlook C3G / IC-MPGN sHLH / FDA filing initiated MAS SEL-212 EU approval New Indications* New medicines* Geographical expansion Beyfortus & Altuviiio (royalties) 2024 NME : New Molecular Entity. Altuvoct is marketed by San
Slide 18: Haematology: Doptelet continues to show strong momentum
Haematology: Doptelet continues to show strong momentum Doptelet +61% ex China Doptelet • US: Increased uptake driven by higher market share and duration of treatment • Europe and international ongoing growth driven by launches and increased market share • Sales growth in the quarter impacted by sal
Slide 19: Haematology: Aspaveli reaching more patients in PNH
Haematology: Aspaveli reaching more patients in PNH Phase 3 data (VALIANT study) in Nephrology expected in H2 2024 Solid Aspaveli/Empaveli launch trajectory Aspaveli/Empaveli • Strong growth momentum across EU, International and Canada as more patients switch from C5i to Aspaveli/ Empaveli seeking o
Slide 20: Haematology: Vonjo launch elements in place for growth in 2024
Haematology: Vonjo launch elements in place for growth in 2024 Vonjo SEK 347 M Highlights • Sales grew 9% (6% at CER) quarter on quarter • Continued momentum from March sales • Various external data sources indicate no volume growth in the myelofibrosis market in H1 2024 • Vonjo has achieved market
Slide 21: Our strategy on Vonjo remains unchanged
Our strategy on Vonjo remains unchanged Still, early launch insights have driven us to revise our go-to-market approach Our Strategy Potential* Status realised Untapped potential market • Take share Changes initiated in the US MF market Expect launches as of 2025; • Expand internationally Good progr
Slide 22: US approach: Building Vonjo based on a sound medical rationale and a more effective team
US approach: Building Vonjo based on a sound medical rationale and a more effective team Building on a strong scientific rationale Evolution to our approach in the US • Devastating disease impacting cytopenia’s1-3 • Changed leadership and expanded sales force • Poor Prognosis of MF patients with man
Slide 23: Haematology: Continued patient growth and geographical expansion
Haematology: Continued patient growth and geographical expansion Elocta Alprolix +14% Q2 +8% Q2 • Growth in number of patients, geographic expansion and favorable impact from phasing • Partly offset by continued price pressure in many regions Sales in SEK million at actual exchange rates; change at
Slide 24: Immunology: Gamifant continued growth in US; Kineret: Increased demand across all regions
Immunology: Gamifant continued growth in US Kineret: Increased demand across all regions Gamifant Kineret SEK 522 M Gamifant SEK 745 M +4% Q2 • Growth driven by: +11% Q2 • Increased patients from new and established centers • Higher average dosing Kineret • Beneficial impact from order phasing • Gro
Slide 25: Q2 2024 Revenue and profit & loss
Q2 2024 Revenue and profit & loss Q2 Q2 Full-year Total revenue (SEK M) Amounts in SEK M 2024 2023 Change 2023 Total revenue 5,442 4,872 12% 22,123 Haematology Immunology Specialty Care Adjusted Gross profit 1,2 4,166 3,478 20% 17,162 6 844 298 6 256 Adjusted Gross margin 1,2 77% 71% 78% 272 EBITA1
Slide 26: Outlook 2024
Outlook 2024 Updated Revenue Anticipated to grow by a low double-digit percentage at CER1 Adjusted EBITA margin Anticipated to be in the mid-30s percentage of revenue 1. Constant exchange rates. 26
Slide 27: Sustainability at Sobi
© @sobl Sustainability at Sobi
Slide 28: Sobi's sustainability strategy supports our strategic business priorities
Sobi’s sustainability strategy supports our strategic business priorities Maintain commitment Always act to patients responsibly Sustainability indices Index 2023 score • Access to treatment • An inclusive and diverse MSCI A (top 26%) • Patient centricity & workplace • Safe, healthy and fair Sustain
Slide 29: Maintain commitment to patients
Maintain commitment to patients For more details: Sustainability performance | Sobi Access to treatment Humanitarian aid Patient centricity • ~ 36,000 people treated* with • Four international patient councils to medicines from Sobi. advise on early clinical development. • Sobi’s main medicines acce
Slide 30: Always act responsibly
Always act responsibly For more details: Sustainability performance | Sobi Caring for employees Reduced footprint Responsible sourcing Compliance • Gender composition (%) • A 77% reduction in CO2- intensity between 2016 95% Mean score 64 95% and 2023 (from 0,3 to 0,07 between completed Code of of So
Slide 31: Pipeline and upcoming news flow
Pipeline and upcoming news flow
Slide 32: Significant events in 2024
Significant events in 2024 Anticipated major pipeline news flow Altuvoct SEL-212 Gamifant FDA submission & EU approval FDA submission Aspaveli Valiant data 2024 H1 2024 H2 Altuvoct – Haemophilia A: Gamifant – sHLH / MAS in • Regulatory approval in EU rheumatological diseases: • Regulatory submission
Slide 33: Continued R&D momentum in 2025
Continued R&D momentum in 2025 Anticipated major pipeline news flow 2025 Altuvoct – Haemophilia A • FREEDOM (Phase 3b) interim data Aspaveli / Empaveli – Nephrology • EU submission • Japan submission Gamifant1 – sHLH / MAS • US decision • Japan submission SEL-212 – Chronic refractory gout • US decis
Slide 34: Current development pipeline
Current development pipeline Major ongoing clinical studies and medicines in registration in a major region or country Pipeline news flow 2024 H2 Aspaveli/Empaveli – C3G & IC-MPGN • VALIANT phase 3 study data readout Doptelet – ITP • Regulatory submission in Japan • Paediatric submission in US & EU
Slide 35: Sobi IR contacts
Sobi IR contacts Investors page on sobi.com Gerard Tobin Jen Kretzmann Jörgen Winroth Head of Investor Relations Manager of Stakeholder Senior advisor Investor gerard.tobin@sobi.com Communication and Corporate Relations, North America +41 79 286 28 83 Access Jorgen.Winroth@sobi.com jennifer.kretzman
Slide 36: Notes on Haemophilia and RSV business
Notes on Haemophilia and RSV business Haemophilia • Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or Altuviiio in the US. • Sobi has final developmen
Slide 37: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2023 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com